Izabela Tworowska Ph.D., M.Sc.Pharm

Chief Scientific Officer & member of BOD


Co-founder of RadioMedix and is leading the radiotherapeutic program starting from the drug discovery to the clinical studies. Originally trained as a clinical pharmacist and organic chemist, Dr. Tworowska completed her PHD training at the Polish Academy of Science and Frankfurt University with postdoctoral fellowship at Rice University, in Houston, TX. She received the International Sigma-Aldrich Award and International Union and Pure and Applied Chemistry Award. Dr. Tworowska publishes in peer-reviewed journals and serves as a member on the NIH panel reviews, NCI radiotherapy groups and journal editorial boards. She oversees all RadioMedix activities related to commercialization of AlphaMedix™ and is responsible for its development (Phase II SBIR Contract)